Do we need to redefine the advanced stage in Parkinson's disease?

被引:0
|
作者
Sesar, Angel [1 ]
Fernandez-Pajarin, Gustavo [1 ]
Ares, Begona [1 ]
Castro, Alfonso [1 ]
机构
[1] Hosp Clin Univ, Movement Disorder Unit, Neurol Dept, Santiago De Compostela, Spain
来源
REVISTA MEXICANA DE NEUROCIENCIA | 2021年 / 22卷 / 04期
关键词
Parkinson's disease; Advanced stage; Post-advanced stage; Dopaminergic symptoms; Non-dopaminergic symptoms; SYDNEY MULTICENTER; SYMPTOMS;
D O I
10.24875/RMN.20000119
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Identifying the advanced stage in Parkinson's disease ( PD) is crucial for shifting from conventional to device-aided therapies. The criteria to define the onset of advanced PD have been based on lengthy and disabling daily off-times, troublesome dyskinesia and complex therapeutic regimes, but have also included invalidating non-dopaminergic symptoms, such as dementia, falls or dysphagia. These last problems usually appear in a much later stage of the advanced PD. The key to the definition of advanced PD should be the lack of adequate PD control of both motor and non-motor dopaminergic symptoms. The patient's judgment about the quality of their response to conventional therapy is also critical to establish the advanced stage. The early identification of this phase allows maintaining the patient's functional state whenever appropriate treatments are applied. We should keep the term advanced stage when the dopaminergic symptoms responsive to device-aided therapy are preponderant. When invalidating non-dopaminergic symptoms dominate the clinical picture, the term post-advanced stage could be more suitable.
引用
收藏
页码:152 / 158
页数:7
相关论文
共 50 条
  • [1] Is there a need to redefine Parkinson's disease?
    Korczyn, Amos D.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 310 (1-2) : 2 - 3
  • [2] Biosensors for Parkinson's Disease: Where Are We Now, and Where Do We Need to Go?
    Maddocks, Grace M.
    Eisenstein, M.
    Soh, H. Tom
    ACS SENSORS, 2024, 9 (09): : 4307 - 4327
  • [3] Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
    Heinzel, Sebastian
    Berg, Daniela
    Binder, Sebastian
    Ebersbach, Georg
    Hickstein, Lennart
    Herbst, Heinz
    Lorrain, Michael
    Wellach, Ingmar
    Maetzler, Walter
    Petersen, Gudula
    Schmedt, Niklas
    Volkmann, Jens
    Woitalla, Dirk
    Amelung, Volker
    FRONTIERS IN NEUROLOGY, 2018, 9
  • [4] Parkinson's Disease and COVID-19: Do We Need to Be More Patient?
    Gonzalez-Latapi, Paulina
    Fearon, Conor
    Fasano, Alfonso
    Lang, Anthony E.
    MOVEMENT DISORDERS, 2021, 36 (02) : 277 - 277
  • [5] Endogenous Regeneration in Parkinson's Disease: Do We Need Orthotopic Dopaminergic Neurogenesis?
    Hermann, Andreas
    Storch, Alexander
    STEM CELLS, 2008, 26 (11) : 2749 - 2752
  • [6] Reply to: "Parkinson's Disease and COVID-19: Do We Need to Be More Patient?"
    Outeiro, Tiago F.
    Krisko, Anita
    MOVEMENT DISORDERS, 2021, 36 (02) : 278 - 279
  • [7] Do patients with late-stage Parkinson's disease still respond to levodopa?
    Fabbri, Margherita
    Coelho, Miguel
    Abreu, Daisy
    Guedes, Leonor Correia
    Rosa, Mario M.
    Costa, Nilza
    Antonini, Angelo
    Ferreira, Joaquim J.
    PARKINSONISM & RELATED DISORDERS, 2016, 26 : 10 - 16
  • [8] Real or imagined: We need a new scale for psychosis in Parkinson's disease
    Pontone, Gregory M.
    Mills, Kelly A.
    Dobkin, Roseanne D.
    Hinkle, Jared T.
    Nirenberg, Melissa J.
    Schneider, Ruth B.
    PARKINSONISM & RELATED DISORDERS, 2024, 121
  • [9] Treatment of advanced stage patients with Parkinson's disease
    Waters, CH
    PARKINSONISM & RELATED DISORDERS, 2002, 9 (01) : 15 - 21
  • [10] Correlation between urinary incontinence and psychosis in patients with advanced-stage Parkinson's disease
    Nakahara, Keiichi
    Kurisaki, Ryoichi
    Nakane, Shunya
    Sakamoto, Tetsuro
    Ikeda, Tokunori
    Yamashita, Tetsuji
    Uekawa, Kazutoshi
    Ando, Yukio
    NEUROLOGY AND CLINICAL NEUROSCIENCE, 2020, 8 (06): : 385 - 389